Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda, Merck Diabetes Drug Combo Shown To Lower Blood Sugar

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical's Actos (pioglitazone) and Merck's Januvia (sitagliptin) have shown in a study to be effective when used with insulin therapy to lower blood sugar in type 2 diabetics. Data from two clinical trials on lowering blood sugar showed a 2.4 percent reduction in a key measure of average blood glucose level over a two- to three-month period. The lowering of A1C levels from 8 percent to 12 percent to a relatively safe level of 7 percent or less was considered statistically significant. The trials combined Merck's new-generation drug with Takeda's older class of drug. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts